ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.848,77
-0,34%
S&P 500
5.959,03
0,48%
Dow Jones
42.824,03
-0,04%
Euro vs US Dollar
1,04089
-0,23%
Bitcoin
93.177,43
-2,03%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ACELYRIN Inc (SLRN)

  7. ACELYRIN Inc (SLRN) News

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DatumZeitQuelleÜberschriftSymbolFirma
10/12/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
10/12/202422h30GlobeNewswire Inc.ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisNASDAQ:SLRNACELYRIN Inc
13/11/202423h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLRNACELYRIN Inc
13/11/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
13/11/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
13/11/202422h00GlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
06/11/202422h00GlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024NASDAQ:SLRNACELYRIN Inc
04/11/202422h11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
24/10/202420h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
16/10/202413h00GlobeNewswire Inc.ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
19/09/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024NASDAQ:SLRNACELYRIN Inc
10/09/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive SurNASDAQ:SLRNACELYRIN Inc
22/08/202413h00GlobeNewswire Inc.ACELYRIN, INC. to Participate in Upcoming Investor ConferencesNASDAQ:SLRNACELYRIN Inc
13/08/202422h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
13/08/202422h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
13/08/202422h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial ResultsNASDAQ:SLRNACELYRIN Inc
06/08/202422h30GlobeNewswire Inc.ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024NASDAQ:SLRNACELYRIN Inc
11/06/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
05/06/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
29/05/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
28/05/202423h20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
25/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
25/05/202401h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
25/05/202401h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202401h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202401h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
14/05/202422h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
09/05/202414h14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN

Kürzlich von Ihnen besucht

COIN
ETHUSD
Ethereum
CCOM
US100
US Tech 100
NYSE
KO
Coca Cola
TG
DTE
Deutsche Telekom
FX
EURJPY
Euro vs Yen
TG
NOV
Novo Nordisk
COIN
BTCUSD
Bitcoin
AMEX
XLE
Energy Select Sector SPDR
TG
DBK
Deutsche Bank
TG
BAYN
Bayer
DBI
MDAX
MDAX
COIN
AVAXUSD
Avalanche
NYSE
DIS
Walt Disney
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten